.gnw_table_border_collapse td.gnw_label_uline, .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Cooper Companies, Inc. Earnings Conference Call. The trial showed that for the full three-year period, the progression in myopia of those wearing MiSight lenses was less than those wearing conventional soft contact lenses. It has been an honor to lead such an outstanding organization,” said Bob. So that makes me feel good. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights. Al White, a 12-year veteran of the company, has now stepped into those roles, effective May 1, to lead the business forward. And I'm not quite sure what the guys are assuming, but it's got to be 5,000 or so as we're exiting the U.S. Yeah, sure. So, I think, at the end of the day, you're not going to see MyDay toric cannibalizing clariti, that's for sure. And finally, I'm happy to report our new fit data was once again very strong this quarter, especially with respect to silicone hydrogel daily fits which bodes well for our future. The MiSight contact by CooperCompanies’ (NYSE:COO) CooperVision lens is a single-use, disposable, soft contact lens that is discarded at the end of each day and is not intended to be worn overnight. .gnw_media_bgcolor { background-color: transparent } Underlying all this is the assumption our global operations largely returning normal in May the beginning of our fiscal third quarter. But that's a positive dynamic. .gnw_table_border_collapse td.gnw_data, .gnw_data {font: 12px Arial; vertical-align: bottom; text-align: left; white-space: nowrap;} But to your question and to your point, the legacy hydrogel business is continuing to decline. Okay. Our next question comes from Joanne Wuensch with Citi. .gnw_border_bottom_solid {border-bottom: solid black 1px !important;} Yeah. Still $200 or something for new wears. And then as the follow-up, the toric performance again this quarter was quite good on a constant currency basis. Market data powered by FactSet and Web Financial Group. That's obviously premium price points and so forth. Right. No question about that. Brian G. Andrews -- Senior Vice President, Chief Financial Officer & Treasurer. Yeah. For CooperVision, all on a constant-currency basis, the Americas grew a healthy 8% led by our daily silicone hydrogel franchises, where we continue to offer the broadest portfolio in the market with MyDay available on a sphere and toric and clariti in a sphere, toric and multifocal. Having said that, we've got -- we have enough product coming off right now that we're going to be able to put up some pretty good growth rates. We're looking at our own rebate activity. said Mr. Weiss. Yeah. And a little apples and oranges there because the 5% is single-use sphere, so we're seeing a lot of our growth coming from those daily torics. You're correct -- so it was $0.38 up to $0.78 so it was a positive $0.40. So can you -- and if I've heard about it, I'm sure you have. Its contact lenses and related products are sold to eye care practices in over 100 countries. Haven't seen frankly too much impact on that either. .gnw_table_border_collapse td.gnw_num_dlinetop, .gnw_num_dlinetop {font: 12px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; border-top: double black 2.5pt;} There is a lot of those docs that we targeted who have pretty decent pediatric practices. Agostino Ricupati Chief Accounting Officer & Senior Vice President, Finance & Tax . How does the interest level look or the backlog, if you would, beyond the first 1,800? We have 20 certified docs in the US right now already prescribing selling the lens. You lowered 1% for the year. We were using the same rates to make life easy and because at the time we were doing the work, they were more similar. Our next question comes from Steve Willoughby with Cleveland Research. Before getting into those details, let me walk through the quarter's performance. I'm wondering how many countries actually is that. Our Q1 tax rate is always tends to be when we started off the year the lowest ETR because we issue equity grants in the first quarter, so that's always going to kind of take us down somewhere around 2% if you were to kind of straight line at the year. It's going to be a little bit smaller than that, the interest was strong. Thank you. CooperConnect serves as CooperVision’s global, companywide employee magazine. You may proceed with your question. Thank you. You don't want to fit them and have them turn around and walk out the door and just buy it online. It starts with myopia, where it's currently estimated that roughly one-third of the world's population is myopic and this will increase to 50% in 2015. We operate in two very healthy markets. But we're assuming that we continue to sell product pretty similar to how we're selling it today and then moving back to normal as we go into Q3. The results showed a rate comparable to the rate of ulcer cases among adults who wear contact lenses daily. Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. The increased incidence of myopia is a global epidemic so it’s exciting to see an FDA-approved product which can now become the standard-of-care within the ophthalmic industry to treat this crisis.”. Okay. .gnw_table_border_collapse td.gnw_label_dline_i25, .gnw_label_dline_i25 {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt; padding-left: 25.0px;} It has extensive five-year clinical data and experience has shown it's safe and easy for children to handle and wear. The effective tax rate was 10%, largely due to the timing of normal equity grants and larger-than-expected Q1 true-ups related to restructuring activity. 11 Click the heart if you like this article! On the PARAGARD DTC, can you update us on how much you anticipate that spend will be this year? Thank you, Al, and good afternoon, everyone. Subscribe to Medical Design & Outsourcing. About The Cooper CompaniesThe Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). And then that remaining portion is -- that remaining $5 million is kind of spread a little bit to a couple of different countries. .gnw_border_top_solid {border-top: solid black 1px !important;} We've been fortunate and now we haven't had any employees infected by the virus that we're aware of. If you're fitting someone in a toric, it's much more challenging for that patient to turn around and walk out buy that online, and be comfortable buying it online. I would now like to turn the call back over to Al White, President and CEO for any further remarks. Our next question comes from Chris Pasquale with Guggenheim. Great. Thank you. Is there a risk that we just lose contact lens sales for a while? We haven't had a lot of push back, so to speak, but certainly a number of questions. And if you look at VSP, I know that's making its way -- that lens is making its way out also.

Beyond20 Not Sending Rolls, Jeu De Hasard En 2 Lettres, Toreador March Lyrics, Nasa Black Knight, Jon Flanagan Wife, Paper Mechanical Toys, Boban Marjanovic Ears, Nrl Rumours 2020, Marge Gunderson Character Analysis,